Staging and Restaging for Hepatocellular Carcinoma: Solution of Confusion? by Huo, Teh‐ia et al.
CoRReSpoNdeNCe Hepatology, January 2019
464
The authors have reported that 68.3% (82/120) of 
patients required renal replacement therapy (RRT). 
RRT would be a confounding factor for comparing 
the response of terlipressin and noradrenaline due to 
a decrease in creatinine levels postdialysis. Can the 
authors clarify regarding the time points used for 
assessment of response to terlipressin or noradrenaline 
among those patients who received RRT?
We would also like to highlight an error in figure 3A. 
The number mentioned in the third row under the col-
umn for day 28 does not match the number shown in 
the figure (should be 12 instead of 18).
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Staging and Restaging for Hepatocellular Carcinoma: Solution of 
Confusion?
TO THE EDITOR:
We read with interest "Restaging Patients With 
Hepatocellular Carcinoma Before Additional 
Treatment Decisions: A Multicenter Cohort Study" by 
Vitale et al.(1) Although it is an elegant study contain-
ing a large cohort of hepatocellular carcinoma (HCC) 
patients, some concerns should be addressed.
The Italian Liver Cancer (ITA.LI.CA) staging sys-
tem was proposed by the Italian investigators to predict 
the outcome of HCC patients. The ITA.LI.CA sys-
tem uses a scoring method (from 0 to 13) to allocate 
patients into four prognostic groups. However, in most 
currently used systems, at least five groups are employed 
to reflect the highly variable outcome of HCC. A more 
recent study further indicated that by using clinically 
available parameters, seven distinct prognostic groups 
can be identified.(2) Notably, the study by Vitale et al. 
only compared ITA.LI.CA with the Barcelona Clinic 
Liver Cancer, the Hong Kong Liver Cancer, and the 
Cancer of the Liver Italian Program systems.(1) This 
is apparently not adequate because other important 
prognostic tools, such as the Japan Integrated System, 
the Model to Estimate Survival in Ambulatory HCC, 
and the Model to Estimate Survival in HCC, were not 
discussed in the study.
Multiple staging systems have been proposed and 
generally claimed to have better prognostic perfor-
mance. The lack of consensus may result from the 
heterogeneous nature of tumor biology and variable 
treatment strategies at initial staging and restaging. 
The Child-Turcotte-Pugh (CTP) classification is used 
in the ITA.LI.CA system. However, a new marker, the 
albumin-bilirubin (ALBI) grade, as a refinement of 
the CTP classification, was proposed as a more reliable 
prognostic marker for HCC.(3) A major disadvantage 
of CTP classification in HCC is that many patients 
who do not have cirrhosis or have only mild cirrhosis 
are classified as CTP class A. Further discrimination 
by the ALBI grade showed that it can identify two 
prognostic groups, implying that not all CTP class A 
patients are the same.(4) Therefore, it is interesting to 
know if the ALBI grade, instead of CTP classifica-
tion, should be used in the ITA.LI.CA system for out-
come prediction. In summary, a more comprehensive 
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evaluation for the existing staging systems for HCC 
should be performed to determine which model has 
the best predictive accuracy. The ALBI grade, as a new 
player in HCC, may be considered to integrate into 
the staging system to further enhance the prognostic 
performance.
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Reply
We read with great interest the comment letter by 
Huo et al., because this letter gives us the possibil-
ity to better explain some aspects of the ITA.LI.CA 
prognostic system that were probably unclear in our 
previous studies.(1,2)
First, the ITA.LI.CA system is a score based on 14 
prognostic subgroups and not only 4: The lowest score 
(ITA.LI.CA score = 0) of the model corresponded to 
the best prognosis, and the highest score (ITA.LI.CA 
score = 13) was associated with the worst prognosis. 
In the original paper(2) in which the ITA.LI.CA score 
was developed and externally validated, and in this 
paper focused on restaging,(1) we stratified our score in 
quartiles only to clearly and legibly represent the dis-
crimination and calibration abilities of the ITA.LI.CA 
system by Kaplan-Meier survival curves.
Second, the ITA.LI.CA score already proved to 
have a better prognostic performance than JIS and 
MESIAH scores in two large Italian and Taiwanese 
cohorts of patients with hepatocellular carcinoma,(2) 
and in a recent independent Italian validation study.(3) 
The aim of our recent study(1) was, therefore, not to 
compare again all the available systems, but only to 
understand the prognostic behavior of prognostic 
systems at restaging compared with first prognostic 
assessment at baseline, and to evaluate how to improve 
them by adding new prognostic variables available only 
at restaging (i.e., progressive disease after 1° therapy, 
Model for End-Stage Liver Disease at restaging, new 
therapeutic decision).
It is true, as suggested by Huo et al., that in none of 
the studies evaluating the ITA.LI.CA score(1-3) has a 
formal comparison with the Taiwanese MESH score 
been performed, mainly because of the fact that this 
score has been proposed simultaneously to the ITA.
LI.CA system. The MESH score, however, seems to 
have some potential limitations in comparison with the 
ITA.LI.CA score mainly related to a simple dichot-
omization of some relevant prognostic variables (i.e., 
tumor burden within vs. beyond Milan criteria, Child 
score 5 vs. ≥6), and to the absence of a strong external 
validation.
Third, we thank our colleagues for the suggestion 
to test the ALBI grade within the ITA.LI.CA system. 
Indeed, in our original paper,(2) we already tested the 
ALBI grade as a potential variable to include in the 
ITA.LI.CA score, but its prognostic ability resulted 
significantly lower than that of the Child Pugh score(2) 
(Supporting Tables S1 and S2).
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